Journal of International Translational Medicine
Citation Search Quick Search Adv Search
Home       Introduction       Editorial Board       Current Issue        Subscribe       Online Publication       About us
Journal of International Translational Medicine
Journal of International Translational Medicine
JITM, ISSN 2227-6394
founded in 2012
Editor-in-chief:Feng Jifeng, China
Open Access
  Instruction for authors
  Online Submission
  Author Guideline
  General Policy
  Copyright Transfer
   Statement
 Conflict of interest
  Disclaimer
  The types of manuscript
  Requirements for
   manuscripts
 
  Reviewing Center
  Peer Review Policy
  Peer Review login
  Editor Work login
  Office Work login
  Editor-in-Chief login
 
  Online Journal
  Accepted
  Online First
 Current Issue
  Archive
  Most Read
  Most Download
  Email Alert
 
  Current Issue
 
2013 Vol. 1, No. 1
Published: 30 March 2013

 
Select | Export to Abstract
       

Polymorphism in the Methylenetetrahydrofolate Reductase and Thymidylate Synthase Gene Predicts for Response to Fluorouracil-based Chemotherapy in Advanced Gastric Cancer Patients Hot!

Lu Jianwei, Gao Changming, Wu Jianzhong, Cao Haixia, Kazuo Tajima, Chen Huanqiu, Chen Jia, Feng Jifeng
Journal of International Translational Medicine, 2013, 1(1): 4-12
Full Text: PDF (258 KB)    
Show Abstract
Objective: Fluorouracil (5-FU) is widely used in the treatment of gastric cancer. Methylenetetrahydrofolate reductase (MTHFR) and thymidylate synthetase (TS) are important targets of many antimetabolites, including 5-FU. The relationship between polymorphism in the MTHFR (C677T, A1298C) and TS (5`-TUR, 3`-UTR) genotypes and sensitivity of gastric cancer to 5-FU-based chemotherapy is investigated in the present study. Methods: 173 patients with advanced gastric cancer were analyzed. All patients were treated with 5-FU-based chemotherapy (FOLFOX, FP and DCF regimen). DNA from peripheral blood leukocytes was obtained before the treatment. All genotypes were detected by PCR-RFLP. 12 germline polymorphisms within 2 genes were analyzed. The genotypes of MTHFR C677T, A1298C and TS 3`-TUR were analyzed in 173 patients while TS 5`-TUR in 135 patients. Results: The overall response rate (RR) was 35.8%. The RR of the DCF regimen group was significantly higher than that of the FP and FOLFOX regimen groups (55.8% vs. 27.1%, 31.1%; P=0.006). The RR of the MTHFR C677T T/T genotype was significantly higher than that of the C/ C and C/T genotypes (73.3% vs. 28.0%; P=0.000). In MTHFR A1298C, a higher RR was observed in A/A genotype compared with the C/C and A/C genotypes (41.8% vs. 21.6%, P=0.011). The RR of -6/-6 bp and -6/+6 bp genotypes in TS 3`UTR was significantly higher than that of +6/+6 bp genotype (40.3% vs. 17.6%, P=0.014). There was no difference in RR according to TS 5`UTR polymorphism (2R/2R and 2R/3R: 41.7% vs. 3R/3R: 36.8%, P=0.487). The RR of MTHFR C677T T/T genotypes in FOLFOX or FP regimens was significantly higher than that of C/C and C/T genotypes (P=0.008, P=0.000) while no difference in DCF regimen. The RR of DCF regimen wassignificantly higher than that of FOLFOX and FP regimens in C/T and C/C genotypes (P=0.000). The MTHFR C677T T/T genotypes had a significantly higher incidence of grade 3/4 emesis (66.7%) and stomatitis (30.0%) than patients with C/T or C/C genotypes (41.3%, 9.8%; P=0.011, 0.003). The MTHFR A1298C A/A genotype had a higher incidence of grade 3/4 stomatitis (17.2%) and diarrhea (13.9%) than patients with A/C and C/C genotypes (3.9%, 2.0%; P=0.025, 0.026). There was no difference in toxicity for patients with TS 5`UTR and TS 3`UTR genotypes. Conclusion: Detection of MTHFR and TS 3`-UTR polymorphism can be used to guide the choice of 5-FU-based chemotherapy for advanced gastric cancer instead of TS 5`-UTR.
       

Analysis on Indications and Causes of Cesarean Section on Pemba Island of Zanzibar in Africa Hot!

Zhou Liping, Zubeir TS, Hamida SA
Journal of International Translational Medicine, 2013, 1(1): 13-17
Full Text: PDF (197 KB)    
Show Abstract
Objective: To explore and analyze the indications and causes of cesarean section on Pemba island of Zanzibar in Africa to improve the quality of obstetrics. Methods: 564 patients performed cesarean section in Abdulla Mzee Hospital of Pemba from January, 2008 to December, 2011 were selected, and statistics was conducted by the method of retrospective analysis. Results: The rate of cesarean section in Abdulla Mzee Hospital of Pemba was 10.01%. The primary causes of cesarean section included cephalopelvic disproportion (27.13%), scar uterus (23.40%), preeclampsia and eclampsia (13.30%), fetal distress in uterus (9.40%), fetal factors (9.75%) and complication of pregnancy (6.91%). Conclusion: Cesarean section plays a great role in the treatment of dystocia, some complications of pregnancy and reducing the mortality of pregnant women and perinatal infants, but in the area with relatively undeveloped medical conditions in Africa, cesarean section still takes great risks. Unnecessary cesarean section cannot reduce the incidence of postpartum hemorrhage and neonatal morbidity. The local medical staff should improve the midwifery technique, establish and perfect the formal antenatal examination system to improve the quality of maternity.
       

Advance on Insulin-like Growth Factor Binding Protein 2 in Lung Cancer and Other Solid Tumors Hot!

Wu Weiqin, Lu Kaihua
Journal of International Translational Medicine, 2013, 1(1): 18-22
Full Text: PDF (220 KB)    
Show Abstract
Increasing evidence has revealed that IGF signalling plays a key role in cellular proliferation, survival, differentiation and senescence. Dysregulation of this signalling pathway is related to the development and progression of many human diseases, including cancer, diabetes and atherosclerosis. Insulin-like growth factor binding protein-2 (IGFBP-2) is reported to be a modulator of the action of insulin-like growth factors (IGFs), whereas IGF-independent effects of IGFBP-2 on cellular proliferation, apoptosis, and mobility have been revealed not only during the embryonic state but also in the pathological state of cancer. IGFBP-2 is involved in the genesis and progress of various malignancies including lung cancer. Recent findings show in many pre-clinical trials that IGFBP-2 may contribute to the transformation and progression of lung cancer. These studies suggest that IGFBP-2 may be a potential therapeutic target for lung cancer. In this review, we provide an overview on IGFBP-2, review corresponding studies investigating the role of IGFBP-2 as a cancer target in multiple tumors and discuss its possible mechanism in lung cancer.
       

Retrospect and Prospect of Translational Medicine Hot!

Feng Jifeng
Journal of International Translational Medicine, 2013, 1(1): 23-26
Full Text: PDF (239 KB)    
Show Abstract
Being a great revolution of medical research, translational medicine tries to establish more directly linkage between the basic research and clinical medical treatment-two-sideway translational channel so as to quickly promote the clinical transformation and feedback of basic research achievements. So far, A lot of effective studies on translational medicine in various medical fields at home and abroad have been carried out, such as tumor, cardiocerebral vascular diseases, obesity, respiratory functional disorder, epilepsy, schizophrenia, organ transplantation, clinical application of stem cells and neural restoration, meanwhile, many fruitful studies on translational medicine are also performed or being performed in different disciplines or professions, and achieves better progress. But many problems are also presented. Therefore, the direction of medical development in 21 century should be fostering the concepts of translational medicine, encouraging the bidirectional cross between basic research staff and clinical doctors as well as focusing on translational achievements and practical application.
 
 
Chinese Editorial Department, Journal of International Translational Medicine (English Edition)
Address: Room 201, 203, 205, No.3 Building, Zijin Lianhe Cubic Square, Nanjing, 210037, China
Website:www.jitm.hk E-mail:jitm2012@jitm.hk;TEL:+86-025-85552880,-86- 4000600047